Wurzer, Alexander http://orcid.org/0000-0002-3628-4688
De Rose, Francesco
Fischer, Sebastian
Schwaiger, Markus
Weber, Wolfgang
Nekolla, Stephan
Wester, Hans-Jürgen
Eiber, Matthias
D’Alessandria, Calogero
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB 824, SFB 824)
Technische Universität München
Article History
Received: 18 January 2024
Accepted: 20 February 2024
First Online: 26 February 2024
Declarations
:
: Not applicable.
: Not applicable.
: HJW, AW, SF and ME are listed as inventors in patent applications for some types of therapeutic rhPSMA. HJW is a founder and shareholder of Scintomics GmbH, Gräfelfing, Germany. ME reports fees from Blue Earth Diagnostics Ltd. (consultant, research funding), Novartis/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker) and Janssen Pharmaceuticals (consultant, speaker’s bureau), Parexel (image review) and Bioclinica (image review). No other potential conflicts of interest relevant to this article were reported.